Synthesis of Glycyrrhetinic Acid-Modified Chitosan 5-Fluorouracil Nanoparticles and Its Inhibition of Liver Cancer Characteristics in Vitro and in Vivo
Nanoparticle drug delivery (NDDS) is a novel system in which the drugs are delivered to the site of action by small particles in the nanometer range. Natural or synthetic polymers are used as vectors in NDDS, as they provide targeted, sustained release and biodegradability. Here, we used the chitosan and hepatoma cell-specific binding molecule, glycyrrhetinic acid (GA), to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS). The synthetic product was confirmed by Fourier transformed infrared spectroscopy (FT-IR) and 1H-nuclear magnetic resonance ( 1H-NMR). By combining GA-CTS and 5-FU (5-fluorouracil), we obtained a GA-CTS/5-FU nanoparticle, with a particle size of 217.2 nm, a drug loading of 1.56% and a polydispersity index of 0.003. The GA-CTS/5-FU nanoparticle provided a sustained release system comprising three distinct phases of quick, steady and slow release. We demonstrated that the nanoparticle accumulated in the liver. In vitro data indicated that it had a dose- and time-dependent anti-cancer effect. The effective drug exposure time against hepatic cancer cells was increased in comparison with that observed with 5-FU. Additionally, GA-CTS/5-FU significantly inhibited the growth of drug-resistant hepatoma, which may compensate for the drug-resistance of 5-FU. In vivo studies on an orthotropic liver cancer mouse model demonstrated that GA-CTS/5-FU significantly inhibited tumor growth, resulting in increased survival time.
References
[1]
Toriumi, F.; Kubota, T.; Saikawa, Y.; Yoshida, M.; Otani, Y.; Watanabe, M.; Kumai, K.; Kitajima, M. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 2004, 24, 2455–2463.
[2]
Johnson, K.R.; Wang, L.; Miller, M.R.; Willingham, M.C.; Fan, W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin. Cancer Res. 1997, 3, 1739–1745.
[3]
Fang, J.Y.; Liu, P.F.; Huang, C.M. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr. Drug Metab. 2008, 9, 592–597, doi:10.2174/138920008785821693.
[4]
Chen, Y.; Wang, X.; Yan, Z.; Wang, J.; Luo, J.; Liu, Q. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. Onkologie 2012, 35, 480–484.
[5]
Takahashi, Y.; Yamashita, K.; Endo, Y.; Sasaki, T.; Mai, M. Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system. Surg. Today 2004, 34, 855–859.
[6]
Oh, I.H.; Min, H.S.; Li, L.; Tran, T.H.; Lee, Y.K.; Kwon, I.C.; Choi, K.; Kim, K.; Huh, K.M. Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials 2013, 34, 6454–6463, doi:10.1016/j.biomaterials.2013.05.017.
[7]
Hamman, J.H. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar. Drugs 2010, 8, 1305–1322, doi:10.3390/md8041305.
[8]
Arulmozhi, V.; Pandian, K.; Mirunalini, S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf. B Biointerfaces 2013, 110C, 313–320, doi:10.1016/j.colsurfb.2013.03.039.
[9]
Javid, A.; Ahmadian, S.; Saboury, A.A.; Kalantar, S.M.; Rezaei-Zarchi, S. Chitosan Coated Superparamagnetic Iron Oxide Nanoparticles for Doxorubicin Delivery: Synthesis and Anticancer Effect against Human Ovarian Cancer Cells. Chem. Biol. Drug Des. 2013, 82, 296–306, doi:10.1111/cbdd.12145.
[10]
Huang, X.; Wang, Y.; Cai, J.P.; Ma, X.Y.; Li, Y.; Cheng, J.W.; Wei, R.L. Sustained release of 5-fluorouracil from chitosan nanoparticles surface modified intra ocular lens to prevent posterior capsule opacification: an in vitro and in vivo study. J. Ocul. Pharmacol. Ther. 2013, 29, 208–215, doi:10.1089/jop.2012.0184.
[11]
Xu, J.; Ma, L.; Liu, Y.; Xu, F.; Nie, J.; Ma, G. Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int. J. Biol. Macromol. 2012, 50, 438–443, doi:10.1016/j.ijbiomac.2011.12.034.
[12]
Yan, S.; Zhu, J.; Wang, Z.; Yin, J.; Zheng, Y.; Chen, X. Layer-by-layer assembly of poly(L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fluorouracil. Eur. J. Pharm. Biopharm. 2011, 78, 336–345, doi:10.1016/j.ejpb.2010.12.031.
[13]
Park, J.H.; Saravanakumar, G.; Kim, K.; Kwon, I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 2010, 62, 28–41, doi:10.1016/j.addr.2009.10.003.
[14]
Yu, J.M.; Li, Y.J.; Qiu, L.Y.; Jin, Y. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: Preparation and in vitro and in vivo characterization. J. Pharm. Pharmacol. 2009, 61, 713–719, doi:10.1211/jpp.61.06.0003.
[15]
He, Z.Y.; Zheng, X.; Wu, X.H.; Song, X.R.; He, G.; Wu, W.F.; Yu, S.; Mao, S.J.; Wei, Y.Q. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int. J. Pharm. 2010, 397, 147–154, doi:10.1016/j.ijpharm.2010.06.029.
Jeong, H.G.; You, H.J.; Park, S.J.; Moon, A.R.; Chung, Y.C.; Kang, S.K.; Chun, H.K. Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol. Res. 2002, 46, 221–227, doi:10.1016/S1043-6618(02)00121-4.
[19]
Lallemand, B.; Gelbcke, M.; Dubois, J.; Prevost, M.; Jabin, I.; Kiss, R. Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents. Mini Rev. Med. Chem. 2011, 11, 881–887, doi:10.2174/138955711796575443.
[20]
Tian, Q.; Wang, X.H.; Wang, W.; Zhang, C.N.; Wang, P.; Yuan, Z. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid. Nanomedicine 2012, 8, 870–879, doi:10.1016/j.nano.2011.11.002.
[21]
Huang, W.; Wang, W.; Wang, P.; Zhang, C.N.; Tian, Q.; Zhang, Y.; Wang, X.H.; Cha, R.T.; Wang, C.H.; Yuan, Z. Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier. J. Mater. Sci. Mater. Med. 2011, 22, 853–863, doi:10.1007/s10856-011-4262-2.
[22]
Negishi, M.; Irie, A.; Nagata, N.; Ichikawa, A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim. Biophys. Acta 1991, 1066, 77–82, doi:10.1016/0005-2736(91)90253-5.
[23]
Patravale, V.B.; Date, A.A.; Kulkarni, R.M. Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 2004, 56, 827–840, doi:10.1211/0022357023691.
[24]
Zhu, L.; Ma, J.; Jia, N.; Zhao, Y.; Shen, H. Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: Preparation, characterization and cytotoxicity studies. Colloids Surf. B Biointerfaces 2009, 68, 1–6, doi:10.1016/j.colsurfb.2008.07.020.
[25]
Ligabue, A.; Marverti, G.; Liebl, U.; Myllykallio, H. Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PLoS One 2012, 7, e47318.
[26]
Nabeya, Y.; Suzuki, T.; Furuya, A.; Koide, N.; Ohkoshi, M.; Takiguchi, M.; Ochiai, T.; Matsubara, H.; Hiwasa, T. Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. Cancer Sci. 2011, 102, 1509–1515, doi:10.1111/j.1349-7006.2011.01978.x.
[27]
Cheng, M.; He, B.; Wan, T.; Zhu, W.; Han, J.; Zha, B.; Chen, H.; Yang, F.; Li, Q.; Wang, W.; et al. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One 2012, 7, e47115.
[28]
Snow, K.; Judd, W. Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br. J. Cancer 1991, 63, 17–28, doi:10.1038/bjc.1991.7.
[29]
Kuo, M.T.; Bao, J.J.; Curley, S.A.; Ikeguchi, M.; Johnston, D.A.; Ishikawa, T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res. 1996, 56, 3642–3644.
[30]
Banerjee, D.; Mayer-Kuckuk, P.; Capiaux, G.; Budak-Alpdogan, T.; Gorlick, R.; Bertino, J.R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta 2002, 1587, 164–173, doi:10.1016/S0925-4439(02)00079-0.
[31]
Violette, S.; Poulain, L.; Dussaulx, E.; Pepin, D.; Faussat, A.M.; Chambaz, J.; Lacorte, J.M.; Staedel, C.; Lesuffleur, T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 2002, 98, 498–504, doi:10.1002/ijc.10146.
[32]
Hibasami, H.; Iwase, H.; Yoshioka, K.; Takahashi, H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int. J. Mol. Med. 2006, 17, 215–219.
[33]
Gianni, M.; Koken, M.H.; Chelbi-Alix, M.K.; Benoit, G.; Lanotte, M.; Chen, Z.; de The, H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998, 91, 4300–4310.
